×

Diagnostics For All Appoints Fran Heller, Former Bristol-Myers Squibb Senior Executive, to Board of Directors

CAMBRIDGE, Mass., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Diagnostics For All, Inc. today announced that Frances K. Heller has joined the non-profit's Board of Directors. Ms. Heller is an accomplished leader in the pharmaceutical and biotech industries with 20 years of experience in business development, licensing and legal affairs. Most recently, she served as senior vice president of business development at Bristol-Myers Squibb and as a trustee of the Bristol-Myers Squibb Foundation. Her appointment to the Board is effective immediately.

"We are thrilled to have Fran join our board. She has that rare combination of strong healthcare industry experience and non-profit expertise. We look forward to her contributions and her unique perspective on the Board," said Marcus Lovell-Smith, CEO of Diagnostics For All.

"Diagnostics For All is addressing one of the world's toughest challenges – how to deliver innovative health care in the poorest and remote parts of the world," said Fran Heller. "It's critically important work and I am proud to be part of the team that is making it happen."

Ms. Heller currently serves as a trustee of the Dana Farber Cancer Institute and is a member of the board of directors at Zafgen, Inc., a public biotech company and Affinivax, a private biotech company. Prior to joining Bristol-Meyers Squibb, she was executive vice president of business development at Exelixis Pharmaceuticals, and prior to joining Exelixis, she served as head of strategic alliances at Novartis Pharmaceuticals. Ms. Heller is a member of the California State Bar and licensed by the U.S. Patent and Trademark Office. She holds a B.S. in biology from Tulane University, an M.A. in biology from American University and a J.D. from Golden Gate University School of Law.

About Diagnostics For All

Incorporated in 2007, Diagnostics For All is a 501(c)(3) non-profit enterprise creating low-cost, easy-to-use point-of-care diagnostic devices specifically designed for the developing world. These devices are elegantly simple and inexpensive. They require minimal training to use, minimal sample preparation, and no electricity or additional equipment. For more information, visit www.dfa.org or email info@dfa.org.

CONTACT: Justin Jackson, Burns McClellan on behalf of Diagnostics For All (212) 213-0006 (Ext 327) jjackson@burnsmc.comSource: Diagnostics For All